# An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients

> **NCT00239044** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 40 (—)

## Conditions studied

- Kidney Transplant Recipients

## Interventions

- **DRUG:** Enteric-coated Mycophenolate sodium (EC-MPS)

## Key facts

- **NCT ID:** NCT00239044
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2005-07
- **Final completion:** —
- **Target enrollment:** 40 (—)
- **Last updated:** 2011-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00239044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00239044, "An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00239044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*